{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T00:40:52Z","timestamp":1760316052442,"version":"build-2065373602"},"reference-count":29,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2002,9,5]],"date-time":"2002-09-05T00:00:00Z","timestamp":1031184000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2002,9,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>BACKGROUND<\/jats:title><jats:p>Docetaxel is associated with severe lymphopenia and increased incidence of nonneutropenic infection. This study investigated the incidence of nonneutropenic infections and\/or febrile episodes in patients with solid tumors receiving frontline docetaxel\u2010based chemotherapy.<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS<\/jats:title><jats:p>Chemotherapy\u2010naive patients with solid tumors treated with docetaxel\u2010based chemotherapy were studied prospectively for the development of nonneutropenic infections.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS<\/jats:title><jats:p>During a 2\u2010year period, 680 cancer patients enrolled in 24 protocols received 2867 cycles of docetaxel\u2010containing chemotherapy. Fifty\u2010three patients (7.8%) developed nonneutropenic infections and\/or febrile episodes. The most common of these were pulmonary infections (<jats:italic>n<\/jats:italic> = 25), <jats:italic>Pneumocystis carinii<\/jats:italic> interstitial pneumonias (<jats:italic>n<\/jats:italic> = 5), and candidal (<jats:italic>n<\/jats:italic> =11), herpetic (<jats:italic>n<\/jats:italic> =4), and cytomegaloviral (<jats:italic>n<\/jats:italic> =3) infections. Thirty\u2010six patients (68%) had severe lymphopenia (&lt; 900 cells per deciliter) and 49 (92%) had less than 400 CD4<jats:sup>+<\/jats:sup> cells per deciliter. Patients with a low CD4<jats:sup>+<\/jats:sup> cell count (\u2264 200 cells per deciliter) had a significantly higher probability to develop opportunistic than common infections (<jats:italic>P<\/jats:italic> = 0.002). The incidence of nonneutropenic infections and\/or febrile episodes was significantly higher in patients treated with docetaxel\/gemcitabine (18.3%; <jats:italic>P<\/jats:italic> = 0.0001) and docetaxel\/CDDP (11.7%; <jats:italic>P<\/jats:italic> = 0.012) than in those treated with docetaxel alone (3.6%). Conversely, 175 patients who received 752 cycles of chemotherapy with paclitaxel\u2010containing regimens and 410 patients who received 2174 cycles with nontaxane\u2010based regimens developed 6 (3.4%; p=0.042) and 12 (3%; p=0.001) nonneutropenic infections, respectively. Less than 10% of the patients of the two latter groups were lymphopenic. The risk of nonneutropenic infection in patients receiving docetaxel\u2010based chemotherapy was 2.38 and 2.8 times higher than in patients receiving paclitaxel and nontaxane\u2010based chemotherapy, respectively.<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS<\/jats:title><jats:p>Patients treated with docetaxel\u2010based chemotherapy are at increased risk of developing nonneutropenic infections. This may be related, at least partly, to severe postchemotherapy CD4<jats:sup>+<\/jats:sup> lymphopenia. Cancer 2002;95:1326\u201333. \u00a9 2002 American Cancer Society.<\/jats:p><jats:p>DOI 10.1002\/cncr.10802<\/jats:p><\/jats:sec>","DOI":"10.1002\/cncr.10802","type":"journal-article","created":{"date-parts":[[2002,10,8]],"date-time":"2002-10-08T18:57:19Z","timestamp":1034103439000},"page":"1326-1333","source":"Crossref","is-referenced-by-count":12,"title":["Nonneutropenic febrile episodes associated with docetaxel\u2010based chemotherapy in patients with solid tumors"],"prefix":"10.1002","volume":"95","author":[{"given":"John","family":"Souglakos","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Athanaslos","family":"Kotsakis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charalambos","family":"Kouroussis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stylianos","family":"Kakolyris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dimitrios","family":"Mavroudis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Konstadinos","family":"Kalbakis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sofia","family":"Agelaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Vlachonikolis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vassilis","family":"Georgoulias","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George","family":"Samonis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2002,9,5]]},"reference":[{"doi-asserted-by":"publisher","key":"e_1_2_5_2_2","DOI":"10.1093\/jnci\/83.4.288"},{"key":"e_1_2_5_3_2","first-page":"4845","article-title":"Experimental antitumour activity of Taxotere (PR 56976, NSC 628503), a taxol analogue","volume":"51","author":"Bissery MC","year":"1991","journal-title":"Cancer Res."},{"doi-asserted-by":"publisher","key":"e_1_2_5_4_2","DOI":"10.1007\/978-1-4615-2007-8_9"},{"issue":"4","key":"e_1_2_5_5_2","first-page":"22","article-title":"Summary of phase II data of docetaxel (Taxotere), an active agent in the first\u2010and second\u2010line treatment of advanced non\u2010small cell lung cancer","volume":"22","author":"Fossela FV","year":"1995","journal-title":"Semin Oncol."},{"doi-asserted-by":"publisher","key":"e_1_2_5_6_2","DOI":"10.1093\/jnci\/87.9.676"},{"issue":"4","key":"e_1_2_5_7_2","first-page":"30","article-title":"Docetaxel (Taxotere) in the treatment of solid tumors other than breast and lung cancer","volume":"22","author":"Kaye SB","year":"1995","journal-title":"Semin Oncol."},{"doi-asserted-by":"publisher","key":"e_1_2_5_8_2","DOI":"10.1097\/00001813-199507004-00005"},{"doi-asserted-by":"publisher","key":"e_1_2_5_9_2","DOI":"10.1097\/00001813-199507004-00004"},{"issue":"4","key":"e_1_2_5_10_2","first-page":"S2","article-title":"Phase II studies of docetaxel in the treatment of various solid tumors","volume":"31","author":"Verweij J","year":"1993","journal-title":"Eur J Cancer."},{"doi-asserted-by":"publisher","key":"e_1_2_5_11_2","DOI":"10.1097\/00001813-199506000-00001"},{"issue":"2","key":"e_1_2_5_12_2","first-page":"3","article-title":"Preclinical evaluation of docetaxel (Taxotere)","volume":"22","author":"Lavelle F","year":"1995","journal-title":"Semin Oncol."},{"doi-asserted-by":"publisher","key":"e_1_2_5_13_2","DOI":"10.1200\/JCO.1999.17.3.862"},{"doi-asserted-by":"publisher","key":"e_1_2_5_14_2","DOI":"10.1002\/1097-0142(20000915)89:6<1380::AID-CNCR23>3.0.CO;2-R"},{"doi-asserted-by":"publisher","key":"e_1_2_5_15_2","DOI":"10.1023\/A:1008278103446"},{"doi-asserted-by":"publisher","key":"e_1_2_5_16_2","DOI":"10.1016\/S0169-5002(98)00028-2"},{"doi-asserted-by":"publisher","key":"e_1_2_5_17_2","DOI":"10.1002\/(SICI)1097-0142(19981115)83:10<2083::AID-CNCR6>3.0.CO;2-I"},{"issue":"14","key":"e_1_2_5_18_2","first-page":"9","article-title":"Docetaxel (Taxotere) and vinorelbine (Navelbine) in the treatment of non\u2010small cell lung cancer","volume":"24","author":"Georgoulias V","year":"1997","journal-title":"Semin Oncol."},{"issue":"14","key":"e_1_2_5_19_2","first-page":"22","article-title":"Docetaxel (Taxotere) and gemcitabine (Gemsar) in the treatment of non\u2010small cell lung cancer: preliminary results","volume":"24","author":"Georgoulias V","year":"1997","journal-title":"Semin Oncol."},{"doi-asserted-by":"publisher","key":"e_1_2_5_20_2","DOI":"10.1007\/s002800050892"},{"doi-asserted-by":"publisher","key":"e_1_2_5_21_2","DOI":"10.1016\/S0959-8049(97)10101-0"},{"doi-asserted-by":"publisher","key":"e_1_2_5_22_2","DOI":"10.1200\/JCO.1996.14.4.1071"},{"key":"e_1_2_5_23_2","first-page":"471","article-title":"Post\u2010chemotherapy lymphopoisis in patients with solid tumors is characterized by CD4+ proliferation","volume":"19","author":"Sarra E","year":"1999","journal-title":"Anticancer Res."},{"volume-title":"Statistical methods in clinical research","year":"1994","author":"Armitage P","key":"e_1_2_5_24_2"},{"doi-asserted-by":"publisher","key":"e_1_2_5_25_2","DOI":"10.1007\/s005200050091"},{"doi-asserted-by":"publisher","key":"e_1_2_5_26_2","DOI":"10.1111\/j.1600-0609.1993.tb00165.x"},{"doi-asserted-by":"publisher","key":"e_1_2_5_27_2","DOI":"10.1093\/oxfordjournals.annonc.a058693"},{"doi-asserted-by":"publisher","key":"e_1_2_5_28_2","DOI":"10.7326\/0003-4819-129-7-199810010-00010"},{"unstructured":"KourousisCh KakolyrisS MavroudisD et al.A phase I study of weekly docetaxel(D) and gemcitabine (G) in advanced non\u2010small cell lung cancer[abstract]. International Congress on Lung Cancer Rhodes Greece 2001:152.","key":"e_1_2_5_29_2"},{"doi-asserted-by":"publisher","key":"e_1_2_5_30_2","DOI":"10.1097\/00000421-200006000-00021"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.10802","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.10802","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T13:55:23Z","timestamp":1760277323000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.10802"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,9,5]]},"references-count":29,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2002,9,15]]}},"alternative-id":["10.1002\/cncr.10802"],"URL":"https:\/\/doi.org\/10.1002\/cncr.10802","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"type":"print","value":"0008-543X"},{"type":"electronic","value":"1097-0142"}],"subject":[],"published":{"date-parts":[[2002,9,5]]}}}